Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.
Harrington BK, Gardner HL, Izumi R, Hamdy A, Rothbaum W, Coombes KR, Covey T, Kaptein A, Gulrajani M, Van Lith B, Krejsa C, Coss CC, Russell DS, Zhang X, Urie BK, London CA, Byrd JC, Johnson AJ, Kisseberth WC. Harrington BK, et al. Among authors: krejsa c. PLoS One. 2016 Jul 19;11(7):e0159607. doi: 10.1371/journal.pone.0159607. eCollection 2016. PLoS One. 2016. PMID: 27434128 Free PMC article. Clinical Trial.
Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices.
Pepin XJH, Moir AJ, Mann JC, Sanderson NJ, Barker R, Meehan E, Plumb AP, Bailey GR, Murphy DS, Krejsa CM, Andrew MA, Ingallinera TG, Slatter JG. Pepin XJH, et al. Among authors: krejsa cm. Eur J Pharm Biopharm. 2019 Sep;142:435-448. doi: 10.1016/j.ejpb.2019.07.011. Epub 2019 Jul 12. Eur J Pharm Biopharm. 2019. PMID: 31306750
Pharmacokinetics and Macrophage Inhibitory Cytokine-1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT-232) in Fed and Fasted Healthy Subjects.
Wong S, Krejsa C, Lee D, Harris A, Simard E, Wang X, Allard M, Podoll T, O'Reilly T, Slatter JG. Wong S, et al. Among authors: krejsa c. Clin Pharmacol Drug Dev. 2022 May;11(5):640-653. doi: 10.1002/cpdd.1070. Epub 2022 Feb 16. Clin Pharmacol Drug Dev. 2022. PMID: 35172043 Free PMC article. Clinical Trial.
Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models.
Krejsa CM, Holly RD, Heipel M, Bannink KM, Johnson R, Roque R, Heffernan J, Hill J, Chin L, Wagener F, Shiota F, Henderson K, Sivakumar PV, Ren HP, Barahmand-Pour F, Foster D, Clegg C, Kindsvogel W, Ponce R, Hughes SD, Waggie K. Krejsa CM, et al. PLoS One. 2013 Jun 25;8(6):e67256. doi: 10.1371/journal.pone.0067256. Print 2013. PLoS One. 2013. PMID: 23825648 Free PMC article.
B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, Hamacher NB, Lantry MM, Maurer M, Krejsa CM, Ellsworth JL, Pederson S, Elkon KB, Wener MH, Dall'Era M, Gross JA. Dillon SR, et al. Among authors: krejsa cm. Arthritis Res Ther. 2010;12(2):R48. doi: 10.1186/ar2959. Epub 2010 Mar 19. Arthritis Res Ther. 2010. PMID: 20302641 Free PMC article.
28 results